Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

por Strand, Vibeke, Kosinski, Mark, Gnanasakthy, Ari, Mallya, Usha, Mpofu, Shephard
Publicado 2014

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

por Mease, Philip J, Kavanaugh, Arthur, Reimold, Andreas, Tahir, Hasan, Rech, Jürgen, Hall, Stephen, Geusens, Piet, Pellet, Pascale, Delicha, Evie Maria, Mpofu, Shephard, Pricop, Luminita
Publicado 2018

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study

por Mease, Philip J., Kavanaugh, Arthur, Reimold, Andreas, Tahir, Hasan, Rech, Juergen, Hall, Stephen, Geusens, Piet, Pellet, Pascale, Delicha, Eumorphia Maria, Pricop, Luminita, Mpofu, Shephard
Publicado 2019

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study

por McInnes, Iain B, Mease, Philip J, Ritchlin, Christopher T, Rahman, Proton, Gottlieb, Alice B, Kirkham, Bruce, Kajekar, Radhika, Delicha, Eumorphia-Maria, Pricop, Luminita, Mpofu, Shephard
Publicado 2017

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

por Nash, Peter, Mease, Philip J., McInnes, Iain B., Rahman, Proton, Ritchlin, Christopher T., Blanco, Ricardo, Dokoupilova, Eva, Andersson, Mats, Kajekar, Radhika, Mpofu, Shephard, Pricop, Luminita
Publicado 2018

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

por van der Heijde, Désirée, Landewé, Robert B., Mease, Philip J., McInnes, Iain B., Conaghan, Philip G., Pricop, Luminita, Ligozio, Greg, Richards, Hanno B., Mpofu, Shephard
Publicado 2016

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

por Mease, Philip, van der Heijde, Désirée, Landewé, Robert, Mpofu, Shephard, Rahman, Proton, Tahir, Hasan, Singhal, Atul, Boettcher, Elke, Navarra, Sandra, Meiser, Karin, Readie, Aimee, Pricop, Luminita, Abrams, Ken
Publicado 2018

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTUR...

por Mease, Philip J, Landewé, Robert, Rahman, Proton, Tahir, Hasan, Singhal, Atul, Boettcher, Elke, Navarra, Sandra, Readie, Aimee, Mpofu, Shephard, Delicha, Eumorphia Maria, Pricop, Luminita, van der Heijde, Desirée
Publicado 2021

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5

por van der Heijde, Désirée, Mease, Philip J, Landewé, Robert B M, Rahman, Proton, Tahir, Hasan, Singhal, Atul, Boettcher, Elke, Navarra, Sandra, Zhu, Xuan, Ligozio, Gregory, Readie, Aimee, Mpofu, Shephard, Pricop, Luminita
Publicado 2020